Log in to search using one of your social media accounts:

 

Improving immunotherapy outcomes with anti-angiogenic treatments and vice versa
Improving immunotherapy outcomes with anti-angiogenic treatments and vice versa, Published online: 13 February 2018; doi:10.1038/nrclinonc.2018.9The combination of immunotherapies with other therapeutic modalities, including anti-angiogenic agents, is currently under investigation to improve the outcomes of patients receiving immunotherapies. In this article, the authors review the effects mediated by anti-angiogenic agents that might increase the efficacy of immunotherapies and discuss the possibility that immunotherapies might increase the efficacy of anti-angiogenic agents and/or promote changes in the tumour vasculatur...
Source: Nature Clinical Practice Oncology - February 13, 2018 Category: Cancer & Oncology Authors: Kabir A. Khan Robert S. Kerbel Source Type: research

Toxicity management after chimeric antigen receptor T cell therapy: one size does not fit 'ALL'
Toxicity management after chimeric antigen receptor T cell therapy: one size does not fit 'ALL', Published online: 13 February 2018; doi:10.1038/nrclinonc.2018.20Toxicity management after chimeric antigen receptor T cell therapy: one size does not fit 'ALL' (Source: Nature Clinical Practice Oncology)
Source: Nature Clinical Practice Oncology - February 13, 2018 Category: Cancer & Oncology Authors: Sattva S. Neelapu Sudhakar Tummala Partow Kebriaei William Wierda Frederick L. Locke Yi Lin Nitin Jain Naval Daver Alison M. Gulbis Sherry Adkins Katayoun Rezvani Patrick Hwu Elizabeth J. Shpall Source Type: research

Toxicity management after chimeric antigen receptor T cell therapy: one size does not fit 'ALL'
Toxicity management after chimeric antigen receptor T cell therapy: one size does not fit 'ALL', Published online: 13 February 2018; doi:10.1038/nrclinonc.2018.19Toxicity management after chimeric antigen receptor T cell therapy: one size does not fit 'ALL' (Source: Nature Clinical Practice Oncology)
Source: Nature Clinical Practice Oncology - February 13, 2018 Category: Cancer & Oncology Authors: David T. Teachey Michael R. Bishop David G. Maloney Stephan A. Grupp Source Type: research

Breast cancer: Recurrent fusions in endocrine-resistant disease
Breast cancer: Recurrent fusions in endocrine-resistant disease, Published online: 06 February 2018; doi:10.1038/nrclinonc.2018.26Breast cancer: Recurrent fusions in endocrine-resistant disease (Source: Nature Clinical Practice Oncology)
Source: Nature Clinical Practice Oncology - February 6, 2018 Category: Cancer & Oncology Authors: Diana Romero Source Type: research

Haematological cancer: Blinatumomab facilitates complete responses
Haematological cancer: Blinatumomab facilitates complete responses, Published online: 06 February 2018; doi:10.1038/nrclinonc.2018.24Haematological cancer: Blinatumomab facilitates complete responses (Source: Nature Clinical Practice Oncology)
Source: Nature Clinical Practice Oncology - February 6, 2018 Category: Cancer & Oncology Authors: Diana Romero Source Type: research

Immunotherapy: Local chemotherapy synergizes with CTLA-4 inhibition
Immunotherapy: Local chemotherapy synergizes with CTLA-4 inhibition, Published online: 06 February 2018; doi:10.1038/nrclinonc.2018.22Immunotherapy: Local chemotherapy synergizes with CTLA-4 inhibition (Source: Nature Clinical Practice Oncology)
Source: Nature Clinical Practice Oncology - February 6, 2018 Category: Cancer & Oncology Authors: Peter Sidaway Source Type: research

Bridging the gap: are animal models consistent with clinical cancer cachexia?
Bridging the gap: are animal models consistent with clinical cancer cachexia?, Published online: 06 February 2018; doi:10.1038/nrclinonc.2018.14Experimental research on cancer-associated cachexia is advancing at an accelerated pace while knowledge of the complex underlying biology of cachexia in humans lags behind. An unmet need exists to accelerate the identification of causal mechanisms in patients with cancer and to determine the parallels between experimental systems and distinct isotypes of human cachexia. (Source: Nature Clinical Practice Oncology)
Source: Nature Clinical Practice Oncology - February 6, 2018 Category: Cancer & Oncology Authors: Vickie E. Baracos Source Type: research

Targeting the IL-6/JAK/STAT3 signalling axis in cancer
Targeting the IL-6/JAK/STAT3 signalling axis in cancer, Published online: 06 February 2018; doi:10.1038/nrclinonc.2018.8The interleukin-6 (IL-6)/Janus kinase (JAK)/signal transducer and activator of transcription 3 (STAT3) pathway is aberrantly hyperactivated in many types of cancer, and such hyperactivation is generally associated with a poor clinical prognosis. In this Review, the authors describe the clinical potential of agents designed to inhibit the IL-6/JAK/STAT3 signalling pathway, either alone or in combination with other agents, in patients with cancer. (Source: Nature Clinical Practice Oncology)
Source: Nature Clinical Practice Oncology - February 6, 2018 Category: Cancer & Oncology Authors: Daniel E. Johnson Rachel A. O ' Keefe Jennifer R. Grandis Source Type: research

Haematological cancer: Dasatinib regulates immune cell function
Haematological cancer: Dasatinib regulates immune cell function, Published online: 06 February 2018; doi:10.1038/nrclinonc.2018.25Haematological cancer: Dasatinib regulates immune cell function (Source: Nature Clinical Practice Oncology)
Source: Nature Clinical Practice Oncology - February 6, 2018 Category: Cancer & Oncology Authors: Diana Romero Source Type: research

Melanoma: Neo/adjuvant BRAF/MEKi improves outcomes
Melanoma: Neo/adjuvant BRAF/MEKi improves outcomes, Published online: 06 February 2018; doi:10.1038/nrclinonc.2018.23Melanoma: Neo/adjuvant BRAF/MEKi improves outcomes (Source: Nature Clinical Practice Oncology)
Source: Nature Clinical Practice Oncology - February 6, 2018 Category: Cancer & Oncology Authors: Peter Sidaway Source Type: research

Diagnosis: CancerSEEK and destroy — a blood test for early cancer detection
Diagnosis: CancerSEEK and destroy — a blood test for early cancer detectionDiagnosis: CancerSEEK and destroy — a blood test for early cancer detection, Published online: 06 February 2018; doi:10.1038/nrclinonc.2018.21Diagnosis: CancerSEEK and destroy — a blood test for early cancer detection (Source: Nature Clinical Practice Oncology)
Source: Nature Clinical Practice Oncology - February 6, 2018 Category: Cancer & Oncology Authors: David Killock Source Type: research

Approvals in 2017: gene therapies and site-agnostic indications
Approvals in 2017: gene therapies and site-agnostic indications, Published online: 31 January 2018; doi:10.1038/nrclinonc.2018.11In 2017, FDA Oncology approved 17 new drug and biologic applications, 32 supplemental drug and biologic applications, and two biosimilar applications in oncology. These actions included landmark approvals of two chimeric antigen receptor T cell therapies and the first site-agnostic, biomarker-defined approval. Three next-generation sequencing 'oncopanels' designed to detect hundreds of somatic genetic aberrations were also approved. (Source: Nature Clinical Practice Oncology)
Source: Nature Clinical Practice Oncology - January 31, 2018 Category: Cancer & Oncology Authors: Gideon M. Blumenthal Richard Pazdur Source Type: research

Paediatrics: Addressing the health burden of childhood cancer survivors — improvements are needed
Paediatrics: Addressing the health burden of childhood cancer survivors — improvements are neededPaediatrics: Addressing the health burden of childhood cancer survivors — improvements are needed, Published online: 31 January 2018; doi:10.1038/nrclinonc.2017.187Recently published data from a large-cohort study confirm the substantial burden of chronic health conditions among childhood cancer survivors, and describe the multiple chronic conditions faced by these individuals. The findings emphasize the need for specialized care in this unique patient population that, as discussed herein, often goes unmet. More mus...
Source: Nature Clinical Practice Oncology - January 31, 2018 Category: Cancer & Oncology Authors: Tara O. Henderson Kevin C. Oeffinger Source Type: research

Haematological cancer: TGFβ-insensitive T cells provide sustained remissions in HL
Haematological cancer: TGFβ-insensitive T cells provide sustained remissions in HLHaematological cancer: TGFβ-insensitive T cells provide sustained remissions in HL, Published online: 31 January 2018; doi:10.1038/nrclinonc.2018.18Haematological cancer: TGFβ-insensitive T cells provide sustained remissions in HL (Source: Nature Clinical Practice Oncology)
Source: Nature Clinical Practice Oncology - January 31, 2018 Category: Cancer & Oncology Authors: Peter Sidaway Source Type: research

Immunotherapy: Desmoplasia is no barrier to PD-1 blockade in melanoma
Immunotherapy: Desmoplasia is no barrier to PD-1 blockade in melanoma, Published online: 31 January 2018; doi:10.1038/nrclinonc.2018.16Immunotherapy: Desmoplasia is no barrier to PD-1 blockade in melanoma (Source: Nature Clinical Practice Oncology)
Source: Nature Clinical Practice Oncology - January 31, 2018 Category: Cancer & Oncology Authors: David Killock Source Type: research

Immunotherapy: Targeting MDSCs with LXR agonists
Immunotherapy: Targeting MDSCs with LXR agonists, Published online: 31 January 2018; doi:10.1038/nrclinonc.2018.17Immunotherapy: Targeting MDSCs with LXR agonists (Source: Nature Clinical Practice Oncology)
Source: Nature Clinical Practice Oncology - January 31, 2018 Category: Cancer & Oncology Authors: David Killock Source Type: research

Immunotherapy: Oncolytic viruses prime antitumour immunity
Immunotherapy: Oncolytic viruses prime antitumour immunity, Published online: 31 January 2018; doi:10.1038/nrclinonc.2018.15Immunotherapy: Oncolytic viruses prime antitumour immunity (Source: Nature Clinical Practice Oncology)
Source: Nature Clinical Practice Oncology - January 31, 2018 Category: Cancer & Oncology Authors: Diana Romero Source Type: research

Gastrointestinal cancer: Novel promising first-line combination
Gastrointestinal cancer: Novel promising first-line combination, Published online: 23 January 2018; doi:10.1038/nrclinonc.2018.7Gastrointestinal cancer: Novel promising first-line combination (Source: Nature Clinical Practice Oncology)
Source: Nature Clinical Practice Oncology - January 23, 2018 Category: Cancer & Oncology Authors: Diana Romero Source Type: research

Prostate cancer: CTCs enable early prediction of response
Prostate cancer: CTCs enable early prediction of response, Published online: 23 January 2018; doi:10.1038/nrclinonc.2018.5Prostate cancer: CTCs enable early prediction of response (Source: Nature Clinical Practice Oncology)
Source: Nature Clinical Practice Oncology - January 23, 2018 Category: Cancer & Oncology Authors: Diana Romero Source Type: research

Exogenous reproductive hormone use in breast cancer survivors and previvors
Exogenous reproductive hormone use in breast cancer survivors and previvors, Published online: 23 January 2018; doi:10.1038/nrclinonc.2017.207The safety of elective exogenous hormonal exposure among breast cancer survivors or women at high risk of having the disease has been debated for decades. Herein, the authors discuss the available data and present clinical recommendations regarding four areas of potential exogenous exposure to hormones: hormonal contraception; systemic hormone-replacement therapy; localized hormone-replacement therapy; and hormonal manipulation for fertility preservation or enhancement. Further resea...
Source: Nature Clinical Practice Oncology - January 23, 2018 Category: Cancer & Oncology Authors: Ines Vaz-Luis Ann H. Partridge Source Type: research

Kidney cancer: PBRM1 loss promotes tumour response to immunotherapy
Kidney cancer: PBRM1 loss promotes tumour response to immunotherapy, Published online: 23 January 2018; doi:10.1038/nrclinonc.2018.12Kidney cancer: PBRM1 loss promotes tumour response to immunotherapy (Source: Nature Clinical Practice Oncology)
Source: Nature Clinical Practice Oncology - January 23, 2018 Category: Cancer & Oncology Authors: Grant Otto Source Type: research

Colorectal cancer: Genomic landscape of mCRC revealed
Colorectal cancer: Genomic landscape of mCRC revealed, Published online: 23 January 2018; doi:10.1038/nrclinonc.2018.10Colorectal cancer: Genomic landscape of mCRC revealed (Source: Nature Clinical Practice Oncology)
Source: Nature Clinical Practice Oncology - January 23, 2018 Category: Cancer & Oncology Authors: Peter Sidaway Source Type: research

Haematological cancer: Improved sensitivity in MRD detection
Haematological cancer: Improved sensitivity in MRD detection, Published online: 23 January 2018; doi:10.1038/nrclinonc.2018.6Haematological cancer: Improved sensitivity in MRD detection (Source: Nature Clinical Practice Oncology)
Source: Nature Clinical Practice Oncology - January 23, 2018 Category: Cancer & Oncology Authors: Diana Romero Source Type: research

Corrigendum: Targeting c-MET in gastrointestinal tumours: rationale, opportunities and challenges
Corrigendum: Targeting c-MET in gastrointestinal tumours: rationale, opportunities and challenges, Published online: 23 January 2018; doi:10.1038/nrclinonc.2018.13Corrigendum: Targeting c-MET in gastrointestinal tumours: rationale, opportunities and challenges (Source: Nature Clinical Practice Oncology)
Source: Nature Clinical Practice Oncology - January 23, 2018 Category: Cancer & Oncology Authors: Conor A. Bradley Manuel Salto-Tellez Pierre Laurent-Puig Alberto Bardelli Christian Rolfo Josep Tabernero Hajrah A. Khawaja Mark Lawler Patrick G. Johnston Sandra Van Schaeybroeck on behalf of the MErCuRIC consortium Source Type: research

Notes from 2017, hopes for 2018
Notes from 2017, hopes for 2018, Published online: 22 January 2018; doi:10.1038/nrclinonc.2018.4Notes from 2017, hopes for 2018 (Source: Nature Clinical Practice Oncology)
Source: Nature Clinical Practice Oncology - January 22, 2018 Category: Cancer & Oncology Source Type: research

Kidney cancer: First-in-class HIF2α antagonist safe and effective
Kidney cancer: First-in-class HIF2α antagonist safe and effectiveKidney cancer: First-in-class HIF2α antagonist safe and effective, Published online: 16 January 2018; doi:10.1038/nrclinonc.2018.3Kidney cancer: First-in-class HIF2α antagonist safe and effective (Source: Nature Clinical Practice Oncology)
Source: Nature Clinical Practice Oncology - January 16, 2018 Category: Cancer & Oncology Authors: Peter Sidaway Source Type: research

Haematological cancer: Daratumumab proves effective in patients with newly diagnosed multiple myeloma
Haematological cancer: Daratumumab proves effective in patients with newly diagnosed multiple myeloma, Published online: 16 January 2018; doi:10.1038/nrclinonc.2018.1Haematological cancer: Daratumumab proves effective in patients with newly diagnosed multiple myeloma (Source: Nature Clinical Practice Oncology)
Source: Nature Clinical Practice Oncology - January 16, 2018 Category: Cancer & Oncology Authors: Peter Sidaway Source Type: research

Will a global fund for cancer be the answer?
Will a global fund for cancer be the answer?, Published online: 16 January 2018; doi:10.1038/nrclinonc.2017.211A call for action has been made for the establishment of a global fund for cancer control, but potential donors have not reacted yet, possibly because this task would require an annual expenditure of billions of dollars. Herein, I suggest a less onerous starting point: targeting childhood cancer in Africa guided by well-designed national cancer control plans. (Source: Nature Clinical Practice Oncology)
Source: Nature Clinical Practice Oncology - January 16, 2018 Category: Cancer & Oncology Authors: Cristina Stefan Source Type: research

CNS cancer: TTFields improve survival
CNS cancer: TTFields improve survival, Published online: 16 January 2018; doi:10.1038/nrclinonc.2018.2CNS cancer: TTFields improve survival (Source: Nature Clinical Practice Oncology)
Source: Nature Clinical Practice Oncology - January 16, 2018 Category: Cancer & Oncology Authors: David Killock Source Type: research

The bone-marrow niche in MDS and MGUS: implications for AML and MM
The bone-marrow niche in MDS and MGUS: implications for AML and MM, Published online: 09 January 2018; doi:10.1038/nrclinonc.2017.197Both multiple myeloma and acute myeloid leukaemia are often preceded by defined precursor stages of neoplasia, which can aid efforts to unravel the mechanisms of disease progression. Herein, the authors review studies of the important roles of microenvironmental factors in promoting the development and progression of haematological cancers in these precursor conditions. Potential therapeutic strategies targeting the abnormal bone-marrow microenvironment are discussed. (Source: Nature Clinical Practice Oncology)
Source: Nature Clinical Practice Oncology - January 9, 2018 Category: Cancer & Oncology Authors: Irene M. Ghobrial Alexandre Detappe Kenneth C. Anderson David P. Steensma Source Type: research

Determinants and clinical implications of chromosomal instability in cancer
Determinants and clinical implications of chromosomal instability in cancer, Published online: 03 January 2018; doi:10.1038/nrclinonc.2017.198Aberrant chromosomal architecture is one of the most common features of cancer and can often lead to chromosomal instability (CIN). In this Review, the authors describe the role of CIN in the development and progression of cancer and the potential to target the therapeutic vulnerabilities created by this process. (Source: Nature Clinical Practice Oncology)
Source: Nature Clinical Practice Oncology - January 3, 2018 Category: Cancer & Oncology Authors: Laurent Sansregret Bart Vanhaesebroeck Charles Swanton Source Type: research

Haematological cancer: Favourable outcomes with CAR T cells
Haematological cancer: Favourable outcomes with CAR T cells, Published online: 03 January 2018; doi:10.1038/nrclinonc.2017.208Haematological cancer: Favourable outcomes with CAR T cells (Source: Nature Clinical Practice Oncology)
Source: Nature Clinical Practice Oncology - January 3, 2018 Category: Cancer & Oncology Authors: Diana Romero Source Type: research

Immunotherapy: HLA-1 genotype influences response to checkpoint inhibitors
Immunotherapy: HLA-1 genotype influences response to checkpoint inhibitors, Published online: 03 January 2018; doi:10.1038/nrclinonc.2017.210Immunotherapy: HLA-1 genotype influences response to checkpoint inhibitors (Source: Nature Clinical Practice Oncology)
Source: Nature Clinical Practice Oncology - January 3, 2018 Category: Cancer & Oncology Authors: Peter Sidaway Source Type: research

Haematological cancer: Brentuximab effective in untreated Hodgkin lymphoma
Haematological cancer: Brentuximab effective in untreated Hodgkin lymphoma, Published online: 28 December 2017; doi:10.1038/nrclinonc.2017.209Haematological cancer: Brentuximab effective in untreated Hodgkin lymphoma (Source: Nature Clinical Practice Oncology)
Source: Nature Clinical Practice Oncology - December 28, 2017 Category: Cancer & Oncology Authors: Peter Sidaway Source Type: research

Perioperative events influence cancer recurrence risk after surgery
Perioperative events influence cancer recurrence risk after surgery, Published online: 28 December 2017; doi:10.1038/nrclinonc.2017.194Despite the achievement of locoregional control, a third of patients undergoing surgery for cancer will have disease recurrence. In this Review, the authors describe the potential to optimize the outcomes of patients with cancer by minimizing inflammation and activation of the sympathetic nervous system in the perioperative period, which is often achievable with simple and cost-effective changes in patient-management strategies. (Source: Nature Clinical Practice Oncology)
Source: Nature Clinical Practice Oncology - December 28, 2017 Category: Cancer & Oncology Authors: Jonathan G. Hiller Nicholas J. Perry George Poulogiannis Bernhard Riedel Erica K. Sloan Source Type: research

Palliative care: Anamorelin provides benefit to patients with cachexia
Palliative care: Anamorelin provides benefit to patients with cachexia, Published online: 19 December 2017; doi:10.1038/nrclinonc.2017.204Palliative care: Anamorelin provides benefit to patients with cachexia (Source: Nature Clinical Practice Oncology)
Source: Nature Clinical Practice Oncology - December 19, 2017 Category: Cancer & Oncology Authors: Peter Sidaway Source Type: research

Bladder cancer: Multi-omic profiling refines the molecular view
Bladder cancer: Multi-omic profiling refines the molecular view, Published online: 19 December 2017; doi:10.1038/nrclinonc.2017.195Muscle-invasive bladder cancer (MIBC) is a heterogeneous disease for which treatment has, historically, lagged behind that of other solid tumour types. A more detailed understanding of the biology of individual tumours, and the identification of molecular features providing prognostic and predictive information is key to the application of personalized care for patients with MIBC. The publication of a study of 412 samples now provides such data. (Source: Nature Clinical Practice Oncology)
Source: Nature Clinical Practice Oncology - December 19, 2017 Category: Cancer & Oncology Authors: Carolyn D. Hurst Margaret A. Knowles Source Type: research

Prostate cancer: Genomic information improves risk prediction
Prostate cancer: Genomic information improves risk prediction, Published online: 19 December 2017; doi:10.1038/nrclinonc.2017.205Prostate cancer: Genomic information improves risk prediction (Source: Nature Clinical Practice Oncology)
Source: Nature Clinical Practice Oncology - December 19, 2017 Category: Cancer & Oncology Authors: Diana Romero Source Type: research

Immunotherapy: dMMR presents opportunities to enhance immunotherapy
Immunotherapy: dMMR presents opportunities to enhance immunotherapy, Published online: 19 December 2017; doi:10.1038/nrclinonc.2017.203Immunotherapy: dMMR presents opportunities to enhance immunotherapy (Source: Nature Clinical Practice Oncology)
Source: Nature Clinical Practice Oncology - December 19, 2017 Category: Cancer & Oncology Authors: David Killock Source Type: research

The evidence framework for precision cancer medicine
The evidence framework for precision cancer medicine, Published online: 19 December 2017; doi:10.1038/nrclinonc.2017.186Precision cancer medicine has the potential to dramatically improve the outcomes of patients with cancer; however, despite the precise nature of the therapies involved, generating reliable evidence of efficacy is often challenging. In this Perspective, the authors describe the challenges and potential solutions that might address the need for evidence in precision cancer medicine. (Source: Nature Clinical Practice Oncology)
Source: Nature Clinical Practice Oncology - December 19, 2017 Category: Cancer & Oncology Authors: Jeffrey A. Moscow Tito Fojo Richard L. Schilsky Source Type: research

Acute lymphoblastic leukaemia in 2017: Immunotherapy for ALL takes the world by storm
Acute lymphoblastic leukaemia in 2017: Immunotherapy for ALL takes the world by storm, Published online: 19 December 2017; doi:10.1038/nrclinonc.2017.176In 2017, three groundbreaking immunotherapies for relapsed and/or refractory B-cell acute lymphoblastic leukaemia (ALL) were approved based on impressive outcomes observed in clinical trials. Additional breakthroughs included seminal research into ALL genomics and the importance of adherence to chemotherapy, which will have direct implications for clinical care. (Source: Nature Clinical Practice Oncology)
Source: Nature Clinical Practice Oncology - December 19, 2017 Category: Cancer & Oncology Authors: David T. Teachey Stephen P. Hunger Source Type: research

Lung cancer: OSNA enables more accurate detection of micrometastases
Lung cancer: OSNA enables more accurate detection of micrometastases, Published online: 19 December 2017; doi:10.1038/nrclinonc.2017.206Lung cancer: OSNA enables more accurate detection of micrometastases (Source: Nature Clinical Practice Oncology)
Source: Nature Clinical Practice Oncology - December 19, 2017 Category: Cancer & Oncology Authors: Peter Sidaway Source Type: research

Colorectal cancer: Defining location effect in nonmetastatic disease
Colorectal cancer: Defining location effect in nonmetastatic disease, Published online: 15 December 2017; doi:10.1038/nrclinonc.2017.202Colorectal cancer: Defining location effect in nonmetastatic disease (Source: Nature Clinical Practice Oncology)
Source: Nature Clinical Practice Oncology - December 15, 2017 Category: Cancer & Oncology Authors: Diana Romero Source Type: research

Immunotherapy: No effect of CAR-T-cell infusion on infection risk
Immunotherapy: No effect of CAR-T-cell infusion on infection risk, Published online: 15 December 2017; doi:10.1038/nrclinonc.2017.200Immunotherapy: No effect of CAR-T-cell infusion on infection risk (Source: Nature Clinical Practice Oncology)
Source: Nature Clinical Practice Oncology - December 15, 2017 Category: Cancer & Oncology Authors: Diana Romero Source Type: research

Lung cancer: First-in-man phase I trial with lorlatinib
Lung cancer: First-in-man phase I trial with lorlatinib, Published online: 15 December 2017; doi:10.1038/nrclinonc.2017.201Lung cancer: First-in-man phase I trial with lorlatinib (Source: Nature Clinical Practice Oncology)
Source: Nature Clinical Practice Oncology - December 15, 2017 Category: Cancer & Oncology Authors: Diana Romero Source Type: research

CAR T cells — what have we learnt?
CAR T cells — what have we learnt?CAR T cells — what have we learnt?, Published online: 15 December 2017; doi:10.1038/nrclinonc.2017.196CAR T cells — what have we learnt? (Source: Nature Clinical Practice Oncology)
Source: Nature Clinical Practice Oncology - December 15, 2017 Category: Cancer & Oncology Source Type: research

Pancreatic cancer: Mass spectrometry indicates malignant potential
Pancreatic cancer: Mass spectrometry indicates malignant potential, Published online: 12 December 2017; doi:10.1038/nrclinonc.2017.199Pancreatic cancer: Mass spectrometry indicates malignant potential (Source: Nature Clinical Practice Oncology)
Source: Nature Clinical Practice Oncology - December 12, 2017 Category: Cancer & Oncology Authors: Peter Sidaway Source Type: research

Breast cancer in 2017: Spurring science, marking progress, and influencing history
Breast cancer in 2017: Spurring science, marking progress, and influencing history, Published online: 12 December 2017; doi:10.1038/nrclinonc.2017.191Data published in 2017 underscore the benefit of optimizing anti-HER2 therapy in early stage high-risk HER2-positive disease, and of capecitabine in patients with residual disease after optimal neoadjuvant therapy. In the advanced-stage setting, endocrine therapy combined with cyclin-dependent kinase 4/6 inhibitors, or olaparib could become the preferred option. (Source: Nature Clinical Practice Oncology)
Source: Nature Clinical Practice Oncology - December 12, 2017 Category: Cancer & Oncology Authors: Jose Perez-Garcia Javier Cortes Source Type: research

Immunotherapy: New or second CARs for ALL
Immunotherapy: New or second CARs for ALL, Published online: 05 December 2017; doi:10.1038/nrclinonc.2017.193Immunotherapy: New or second CARs for ALL (Source: Nature Clinical Practice Oncology)
Source: Nature Clinical Practice Oncology - December 5, 2017 Category: Cancer & Oncology Authors: David Killock Source Type: research

Lung cancer: Osimertinib strengthens the frontline
Lung cancer: Osimertinib strengthens the frontline, Published online: 05 December 2017; doi:10.1038/nrclinonc.2017.192Lung cancer: Osimertinib strengthens the frontline (Source: Nature Clinical Practice Oncology)
Source: Nature Clinical Practice Oncology - December 5, 2017 Category: Cancer & Oncology Authors: David Killock Source Type: research